Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06691945 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Not yet
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
NCT06691945 is a Phase 3 study that has not yet begun recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 700 participants.
The verdict
NCT06691945, a Phase 3 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center, Houston.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
Study Summary
The purpose of this study is to decrease the likelihood of composite postpartum hemorrhage (PPH) morbidity, which consists of i) Estimated or quantified blood loss of 1,500 mL or more, ii) transfusion of any blood products or iii) hysterectomy
Interventions
- COMBINATION_PRODUCT Saline delivered using an intrauterine pressure catheter (IUPC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06691945
The ClinicalTrials.gov registry entry for NCT06691945 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saline delivered using an intrauterine pressure catheter (IUPC) is the first listed.
NCT06691945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06691945 about?
NCT06691945 is a clinical study titled "Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage". The purpose of this study is to decrease the likelihood of composite postpartum hemorrhage (PPH) morbidity, which consists of i) Estimated or quantified blood loss of 1,500 mL or more, ii) transfusion of any blood products or iii) hysterectomy
What is the current status of trial NCT06691945?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2024-11-11. Estimated completion is 2027-05-01.
What interventions are being tested in trial NCT06691945?
The interventions under investigation include: Saline delivered using an intrauterine pressure catheter (IUPC) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06691945?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.